Details of the Drug

General Information of Drug (ID: DM3OWT4)

Drug Name

Tindamax

Synonyms

Tinidazole (oral), Mission Pharmacal

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

247.27

Topological Polar Surface Area (xlogp)

-0.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 901.6 mgh/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: 98% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.6 mL/min/kg [6]
Elimination: 22.5% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 13.2 +/- 1.4 hours [6]
Metabolism: The drug is metabolized via the hepatic [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 134.66815 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.8% [6]
Vd: The volume of distribution (Vd) of drug is 50 L [8]
Water Solubility: The ability of drug to dissolve in water is measured as 20 mg/mL [4]

Chemical Identifiers

Formula: C8H13N3O4S
IUPAC Name: 1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole
Canonical SMILES: CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C
InChI: InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3
InChIKey: HJLSLZFTEKNLFI-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5479
ChEBI ID: CHEBI:63627
CAS Number: 148159-84-6
DrugBank ID: DB00911
TTD ID: D0O4SE
INTEDE ID: DR1596
ACDINA ID: D00678

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Nitroreductase (NTR)	DEAN5EW	NFSB_ENTCL	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tindamax (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Tindamax caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[20]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Tindamax caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[21]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Tindamax caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[22]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Tindamax caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Tindamax caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[24]
Anisindione	DM2C48U	Moderate	Decreased metabolism of Tindamax caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[25]
Mycophenolic acid	DMU65NK	Moderate	Altered absorption of Tindamax due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[26]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Tindamax caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[27]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Tindamax caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Tindamax caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[29]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Tindamax caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Tindamax caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Tindamax caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[32]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Tindamax caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[33]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Tindamax caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[34]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Tindamax caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[35]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Tindamax caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[36]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Tindamax and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[37]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Tindamax caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Tindamax and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Tindamax caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[40]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Tindamax caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[31]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Tindamax caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[41]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Tindamax caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[42]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Tindamax caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[20]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Tindamax caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[43]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Tindamax caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[44]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Tindamax caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[20]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Tindamax and Thalidomide.	Multiple myeloma [2A83]	[39]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Tindamax caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Tindamax caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[45]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Tindamax caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[46]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Tindamax caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[47]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Tindamax caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[48]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Tindamax caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[49]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Tindamax caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[50]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Tindamax caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[20]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Tindamax caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[51]
LEE011	DMMX75K	Moderate	Decreased metabolism of Tindamax caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[52]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Tindamax caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[53]
-----------


⏷ Show the Full List of 40 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tinidazole 250 mg tablet	250 mg	Oral Tablet	Oral
Tinidazole 500 mg tablet	500 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9	FDA label of Tinidazole. The 2020 official website of the U.S. Food and Drug Administration.
10	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
11	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
22	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
23	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
24	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
25	Dean RP, Talbert RL "Bleeding associated with concurrent warfarin and metronidazole therapy." Drug Intell Clin Pharm 14 (1980): 864-6.
26	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
27	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
28	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
29	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
30	Blyden GT, Scavone JM, Greenblatt DJ "Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam." J Clin Pharmacol 28 (1988): 240-5. [PMID: 3360972]
31	Gupte S "Phenobarbital and metabolism of metronidazole." N Engl J Med 308 (1983): 529. [PMID: 6823276]
32	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
33	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
34	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
35	Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983): 509-15. [PMID: 6668631]
36	Product Information. Tindamax (tinidazole). Presutti Laboratories Inc, Arlington Heights, IL.
37	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
38	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
39	Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
40	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
41	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
42	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
44	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
45	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
46	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
47	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
48	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
49	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
50	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
51	Cerner Multum, Inc. "Australian Product Information.".
52	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
53	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.